C12N 2760/18022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 60 US grants and 71 published applications in this corpus.
Search patents in C12N- Granted patents
- 60
- Published applications
- 71
- Assignees
- 42
- Inventors
- 139
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 7 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 1 |
| 2003 | 3 | 1 |
| 2004 | 1 | 4 |
| 2005 | 2 | 2 |
| 2006 | 1 | 3 |
| 2007 | 1 | 2 |
| 2008 | 1 | 1 |
| 2009 | 3 | 4 |
| 2010 | 2 | 7 |
| 2011 | 4 | 4 |
| 2012 | 1 | 1 |
| 2013 | 1 | 0 |
| 2014 | 2 | 2 |
| 2015 | 1 | 2 |
| 2016 | 4 | 4 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 2 | 1 |
| 2020 | 0 | 4 |
| 2021 | 3 | 2 |
| 2022 | 2 | 11 |
| 2023 | 1 | 1 |
| 2024 | 2 | 2 |
| 2025 | 4 | 6 |
| 2026 | 4 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant neuraminidase and uses thereof16 Jun 2026US 12,655,408 B2Icahn School of Medicine at Mount Sinai
- Mumps and measles virus immunogens and their use26 May 2026US 12,636,360 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- RNA construct10 Mar 2026US 12,569,548 B2Imperial College Innovations Limited
- Fusosome compositions and uses thereof5 Aug 2025US 12,378,578 B2Flagship Pioneering Innovations V, Inc.
- Mumps and measles virus immunogens and their use20 Aug 2026US 2026/0240984 A1The United States of America, as represented by the Secretary, Department of Health and Human Ser.
- Engineered protein g fusogens and related lipid particles and methods thereof13 Aug 2026US 2026/0234669 A1Sana Biotechnology, Inc.
- Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells11 Jun 2026US 2026/0158087 A1Mayo Foundation for Medical Education and Research
- Adapter-based retroviral vector system for the selective transduction of target cells7 May 2026US 2026/0125703 A1Miltenyi Biotec GmbH
- Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof9 Apr 2026US 2026/0098062 A1Sana Biotechnology, Inc.
Most cited
By later US patents
- Synthetic peptide inhibitors of HIV transmission102US 5,464,933 ADuke University · 1995
- Simian immunodeficiency virus peptides with antifusogenic and antiviral activities47US 6,017,536 ATrimeris, Inc. · 2000
- Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission37US 6,060,065 ADuke University · 2000
- Methods and interferon deficient substrates for the propagation of viruses37US 6,852,522 B1Mount Sinai School of Medicine of New York University · 2005
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals35US 6,669,943 B1Mount Sinai School of Medicine of New York University · 2003